Stille AB (STO:STIL)
Sweden
· Delayed Price · Currency is SEK 241.50
-12.50 (-4.92%)
Apr 28, 2026, 5:29 PM CET
Stille AB Revenue
Stille AB had revenue of 179.07M SEK in the quarter ending March 31, 2026, with 38.50% growth. This brings the company's revenue in the last twelve months to 617.41M, up 10.34% year-over-year. In the year 2025, Stille AB had annual revenue of 567.63M, down -0.41%.
Revenue (ttm)
617.41M
Revenue Growth
+10.34%
P/S Ratio
3.51
Revenue / Employee
2.94M
Employees
208
Market Cap
2.17B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 567.63M | -2.32M | -0.41% |
| Dec 31, 2024 | 569.95M | 275.06M | 93.27% |
| Dec 31, 2023 | 294.89M | 48.54M | 19.70% |
| Dec 31, 2022 | 246.35M | 59.26M | 31.68% |
| Dec 31, 2021 | 187.09M | 44.46M | 31.17% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 28.24B |
| Getinge AB | 34.09B |
| Sectra AB | 3.52B |
| Camurus AB | 2.27B |
| Vicore Pharma Holding AB | 3.82M |
| Hansa Biopharma AB | 190.49M |
| Egetis Therapeutics AB | 62.40M |
| Flerie AB | 1.80M |
Stille AB News
- 4 days ago - Stille AB Earnings Call Transcript: Q1 2026 - Transcripts
- 2 months ago - Stille AB (OSTO:STIL) Q4 2025: Everything You Need to Know Ahead of Earnings - GuruFocus
- 6 months ago - Stille AB (OSTO:STIL) Q3 2025 Earnings Report Preview: What To Expect - GuruFocus
- 1 year ago - Stille AB (OSTO:STIL) Q4 2024 Earnings Report Preview: What to Look For - GuruFocus